HLA-C and neoplasm: Using peptide-major histocompatibility complex (MHC) tetramers or quantitative assessments of a specific region of the T cell receptor (TCR, also known as CDR3) that recognizes the MHC/epitope of interest can increase the frequency of tumor-reactive cells [48].